Melarsomine Dihydrochloride 50 Mg/ Injection

Verify with FDA CVM →

48 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
48
Total Reports
2
Deaths Reported
420.0%
Death Rate

Active Ingredients

Melarsomine Dihydrochloride 50 Mg/ Injection

Administration Routes

IntramuscularUnknownIntravenousParenteral

Species Affected

Dog 48

Most Affected Breeds

Beagle 5
Terrier - Bull - American Pit 4
Terrier (unspecified) 3
Retriever - Golden 3
Retriever - Labrador 3
Chihuahua 3
Collie - Border 2
Crossbred Canine/dog 2
Bulldog - French 2
Shepherd Dog - German 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 20
Vomiting 7
Panting 6
Diarrhoea 5
Shaking 3
Injection site lump 3
Limb weakness 3
Pain NOS 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Injection site pain 2
Lethargy (see also Central nervous system depression in Neurological) 2
Injection site swelling 2

Outcome Breakdown

Outcome Unknown
31 (64.6%)
Recovered/Normal
8 (16.7%)
Ongoing
7 (14.6%)
Died
2 (4.2%)

Data Summary

Metric Value
Total adverse event reports 48
Reports involving death 2
Case-fatality rate (reported events) 420.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Melarsomine Dihydrochloride 50 Mg/ Injection Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 48 adverse event reports referencing Melarsomine Dihydrochloride 50 Mg/ Injection, including 2 reports in which the animal died — a 420.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Melarsomine Dihydrochloride 50 Mg/ Injection. Reported administration routes include Intramuscular, Unknown, Intravenous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Melarsomine Dihydrochloride 50 Mg/ Injection reports are Dog (48 reports), with Dog accounting for the largest share. Within those species, Beagle (5), Terrier - Bull - American Pit (4), Terrier (unspecified) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Melarsomine Dihydrochloride 50 Mg/ Injection are Lack of efficacy (endoparasite) - heartworm (20), Vomiting (7), Panting (6), Diarrhoea (5). Of the 48 reports with a coded outcome, Outcome Unknown is the leading category at 64.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Melarsomine Dihydrochloride 50 Mg/ Injection.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial